Mindset Pharma Past Earnings Performance

Past criteria checks 0/6

Mindset Pharma's earnings have been declining at an average annual rate of -10.6%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 124.8% per year.

Key information

-10.6%

Earnings growth rate

9.3%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate124.8%
Return on equityn/a
Net Margin-78.8%
Last Earnings Update31 Mar 2023

Recent past performance updates

No updates

Recent updates

Is Mindset Pharma (CSE:MSET) In A Good Position To Deliver On Growth Plans?

Jun 02
Is Mindset Pharma (CSE:MSET) In A Good Position To Deliver On Growth Plans?

Companies Like Mindset Pharma (CSE:MSET) Can Afford To Invest In Growth

Sep 18
Companies Like Mindset Pharma (CSE:MSET) Can Afford To Invest In Growth

We're Interested To See How Mindset Pharma (CSE:MSET) Uses Its Cash Hoard To Grow

Jun 05
We're Interested To See How Mindset Pharma (CSE:MSET) Uses Its Cash Hoard To Grow

Revenue & Expenses Breakdown

How Mindset Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:MSET Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 238-649
31 Dec 228-539
30 Sep 226-967
30 Jun 224-17107
31 Mar 222-21127
31 Dec 210-21126
30 Sep 210-16104
30 Jun 210-1242
31 Mar 210-721

Quality Earnings: MSET is currently unprofitable.

Growing Profit Margin: MSET is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if MSET's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare MSET's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MSET is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).


Return on Equity

High ROE: MSET's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/28 02:49
End of Day Share Price 2023/10/26 00:00
Earnings2023/03/31
Annual Earnings2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mindset Pharma Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stefan QuennevilleEchelon Wealth Partners Inc.
Patrick TrucchioH.C. Wainwright & Co.